00:26:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-15 Kvartalsrapport 2025-Q1
2025-01-15 Årsstämma 2025
2024-10-09 Bokslutskommuniké 2024
2024-07-10 Kvartalsrapport 2024-Q3
2024-04-10 Kvartalsrapport 2024-Q2
2024-01-11 Ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 Årsstämma 2024
2024-01-10 Kvartalsrapport 2024-Q1
2023-10-11 Bokslutskommuniké 2023
2023-07-14 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.
2022-03-29 16:30:00

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Sunitinib Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals in Sweden and Norway are expected to follow upon finalized national reviews.

Sunitinib is a prescription drug used to treat specific types of cancer in the kidney (advanced RCC), pancreas (pNET) and stomach (GIST). Sunitinib works by stopping tumour cells multiplying rapidly and also by reducing the growth of new blood vessels in the tumour. Sunitinib has its effect by targeting receptor tyrosine kinases (RTKs) which are receptors on the surface of cells which are important for the development and progression of some types of cancer.

 “We are pleased to expand our portfolio of oncology products with the registration of Sunitinib Newbury in Denmark. The approval of Sunitinib Newbury is the first registration obtained in Denmark – and we now have obtained registration of various products in all three Scandinavian markets.”, says Lars Minor - CEO, Newbury Pharmaceuticals.

Sunitinib Newbury is part of the oncology pipeline with 11 products expected to be registered in the years ahead. The launch of Sunitinib Newbury will be subject to individual timelines per country and subject to timing and acceptance of tenders.